Join the Oncology Voice Network. Join for Free
How to Create a GREAT MSL Team Culture
Chad Fellers team dynamics in medical affairs team-centric culture fostering development recruiting for cultural fit

How to Create a GREAT MSL Team Culture


Share This Article


Summary

In this episode, Chad Fellers joins to discuss the crucial elements of team dynamics and leadership in medical affairs. Chad shares insights into his background, emphasizing the importance of a team-centric culture and how positive intent in communication extends beyond the workplace. The conversation delves into the significance of trust, fostering development, and recruiting for cultural fit to ensure career satisfaction. Chad also reflects on adapting team culture during the pandemic, offering practical strategies. The episode concludes with a nod to the podcast's mission and encouragement for listener engagement.

Chad Fellers, Director, Medical Science Liaisons at Harmony Biosciences discusses how to develop a GREAT MSL team culture.

Chad shares…

👉 His strategy, philosophy, and key ingredients for a great team culture

👉 Why culture is so important and the benefits of a great culture

👉 Why a “sense of ownership” is so important

👉 How the pandemic and the virtual world affected the team culture

👉 His “Lead vs manage” philosophy and how to cater to the individual team member for career satisfaction

Click for Source
Chad Fellers, team dynamics in medical affairs, team-centric culture, fostering development, recruiting for cultural fit

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology
OVN Avatar Yan Ji, Jin Y. Jin, David M. Hyman, Geoffrey Kim and Ajit Suri

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology

Article
The Oncology Data Network (ODN): Methodology, Challenges, and Achievements
OVN Avatar Ashley Woolmore , Dirk Arnold , Jean‐Yves Blay , Christian Buske , Alfredo Carrato , Winald Gerritsen , Marc Peeters , Jesus Garcia‐Foncillas , David Kerr

The Oncology Data Network (ODN): Methodology, Challenges, and Achievements

Article
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
OVN Avatar Alyson Haslam, PhD; Vinay Prasad, MD, MPH

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs

Article
Loose Regulatory Standards Portend a New Era of Imprecision Oncology
OVN Avatar Ali Raza Khaki

Loose Regulatory Standards Portend a New Era of Imprecision Oncology

Article
Expert perspectives live from ASCO® 2025
Partner Avatar iNIZIO

Expert perspectives live from ASCO® 2025

Article
Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities
OVN Avatar Nidal Al-Huniti, Yan Feng, Jingyu (Jerry) Yu, Zheng Lu, Mario Nagase, Diansong Zhou, Jennifer Sheng

Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities

Explore OVN